Pathways & interactions
PRAME family (IPR026271)
Short name: PRAME_family
Preferentially expressed antigen of melanoma (PRAME) was first isolated as a human melanoma antigen by cDNA expression cloning using melanoma-reactive cytotoxic Tcells (CTL). RAME is a tumor associated antigen (TAA) of particular interest since it is widely expressed by lymphoid and myeloid malignancies and solid tumors, including melanomas, sarcomas, head and neck cancers, small-cell lung carcinomas and renal cell cancers. In normal tissues, PRAME expression has been reported in testis and low levels are found in endometrium, ovaries and adrenals[PMID: 9047241, PMID: 17108098, PMID: 9753074, PMID: 16044453]. However, the PRAME gene is also expressed, although at a lower intensity, in CD34+ stem cells from healthy donors, which might constitute a problem for its application as a target in tumor immunotherapy [PMID: 11943337]. Epigenetic events represent the main mechanism regulating the expression of PRAME including DNA methylation of several promoter regions [PMID: 18282509, PMID: 17382387].
GO:0043066 negative regulation of apoptotic process
GO:0045596 negative regulation of cell differentiation
GO:0048387 negative regulation of retinoic acid receptor signaling pathway
GO:0045892 negative regulation of transcription, DNA-templated
GO:0008284 positive regulation of cell proliferation
GO:0042974 retinoic acid receptor binding
No terms assigned in this category.
- PIRSF038286 (PRAME)